Mark Pollack to Phobic Disorders
This is a "connection" page, showing publications Mark Pollack has written about Phobic Disorders.
Connection Strength
6.300
-
Response to Silberman. Am J Psychiatry. 2014 Jul; 171(7):795-6.
Score: 0.486
-
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
Score: 0.470
-
Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
Score: 0.459
-
D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013 Dec; 81(6):1100-12.
Score: 0.457
-
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul; 170(7):751-8.
Score: 0.454
-
An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
Score: 0.246
-
Relationship between adult social phobia and childhood anxiety. Braz J Psychiatry. 2003 Jun; 25(2):96-9.
Score: 0.226
-
History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis. 2002 Jul; 190(7):453-6.
Score: 0.212
-
New advances in the management of anxiety disorders. Psychopharmacol Bull. 2002; 36(4):79-94.
Score: 0.205
-
Prevalence of childhood ADHD among patients with Generalized Anxiety Disorder and a comparison condition, Social Phobia. Depress Anxiety. 2001; 13(4):190-1.
Score: 0.191
-
Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 12:24-9.
Score: 0.191
-
Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry. 1999; 60 Suppl 9:20-6.
Score: 0.166
-
Social phobia: an update. Harv Rev Psychiatry. 1998 Jan-Feb; 5(5):247-59.
Score: 0.155
-
Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
Score: 0.155
-
The pharmacotherapy of social phobia. Int Clin Psychopharmacol. 1996 Jun; 11 Suppl 3:71-5.
Score: 0.139
-
Smiles may go unseen in generalized social anxiety disorder: evidence from binocular rivalry for reduced visual consciousness of positive facial expressions. J Anxiety Disord. 2013 Oct; 27(7):619-26.
Score: 0.114
-
Development of a brief version of the Social Phobia Inventory using item response theory: the Mini-SPIN-R. Behav Ther. 2013 Dec; 44(4):651-61.
Score: 0.112
-
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry. 2013 Jun 01; 73(11):1054-8.
Score: 0.110
-
Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013 Feb; 47(2):168-74.
Score: 0.108
-
Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depress Anxiety. 2012 Nov; 29(11):924-30.
Score: 0.106
-
Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add? J Anxiety Disord. 2012 Aug; 26(6):665-72.
Score: 0.105
-
Mood regulation and quality of life in social anxiety disorder: an examination of generalized expectancies for negative mood regulation. J Anxiety Disord. 2012 Apr; 26(3):435-41.
Score: 0.103
-
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
Score: 0.089
-
Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. Depress Anxiety. 2009; 26(11):1027-32.
Score: 0.083
-
A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety. 2008; 25(6):496-505.
Score: 0.077
-
Oxytocin levels in social anxiety disorder. CNS Neurosci Ther. 2008; 14(3):165-70.
Score: 0.077
-
Clonazepam in the treatment of panic disorder and agoraphobia. Psychopharmacol Bull. 1987; 23(1):141-4.
Score: 0.072
-
Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol. 1986 Oct; 6(5):302-4.
Score: 0.071
-
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
Score: 0.068
-
An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
Score: 0.068
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.061
-
WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
Score: 0.057
-
Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003 May; 18(3):169-72.
Score: 0.056
-
Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord. 2002 May; 69(1-3):209-17.
Score: 0.052
-
Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress Anxiety. 2001; 14(4):209-13.
Score: 0.048
-
A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000 Jul-Aug; 14(4):345-58.
Score: 0.046
-
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
Score: 0.042
-
Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998 Jul; 155(7):992-3.
Score: 0.040
-
Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord. 1997 Sep-Oct; 11(5):499-502.
Score: 0.038
-
Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
Score: 0.038
-
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
Score: 0.030
-
Cortico-limbic responses to masked affective faces across ptsd, panic disorder, and specific phobia. Depress Anxiety. 2014 Feb; 31(2):150-9.
Score: 0.028
-
Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan; 70(1):87-97.
Score: 0.027
-
Major depression in panic disorder patients with comorbid social phobia. J Affect Disord. 1991 Jul; 22(3):171-7.
Score: 0.025
-
Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry. 1990 Dec; 51 Suppl A:12-6.
Score: 0.024
-
Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990 Nov; 51(11):470-2.
Score: 0.024
-
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res. 1989 Jun; 28(3):345-50.
Score: 0.021
-
Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. J Affect Disord. 2007 Jan; 97(1-3):91-9.
Score: 0.017
-
Effects of parental anxiety disorders in children at high risk for panic disorder: a controlled study. J Affect Disord. 2006 Aug; 94(1-3):191-7.
Score: 0.017
-
Complicated grief and its correlates in patients with bipolar disorder. J Clin Psychiatry. 2005 Sep; 66(9):1105-10.
Score: 0.016
-
Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996 Jun 20; 39(1):31-8.
Score: 0.009
-
Childhood history of anxiety in adults with panic disorder: association with anxiety sensitivity and comorbidity. Harv Rev Psychiatry. 1994 Jan-Feb; 1(5):288-93.
Score: 0.007